BARD1 mutation
|
Prostate Cancer
|
BARD1 mutation
|
Prostate Cancer
|
olaparib Sensitive: A2 - Guideline
|
olaparib Sensitive: A2 - Guideline
|
BARD1 mutation
|
Ovarian Cancer
|
BARD1 mutation
|
Ovarian Cancer
|
olaparib Sensitive: B - Late Trials
|
olaparib Sensitive: B - Late Trials
|
BARD1 mutation
|
HER2 Negative Breast Cancer
|
BARD1 mutation
|
HER2 Negative Breast Cancer
|
durvalumab Sensitive: C2 – Inclusion Criteria
|
durvalumab Sensitive: C2 – Inclusion Criteria
|